LABORATORY RESEARCH Functional Genomics Reveal That the Serine Synthesis Pathway Is Essential in Breast Cancer Scientists developed a method for identifying novel cancer targets via negative-selection RNA interference screening using a human breast cancer xenograft model at an orthotopic site in the mouse. [Nature] Sensitization of BCL-2–Expressing Breast Tumors to Chemotherapy by the BH3 Mimetic ABT-737 Overexpression of the prosurvival protein BCL-2 is common in breast cancer. Here researchers have explored its role as a potential therapeutic target in this disease. [Proc Natl Acad Sci U S A] Asymmetric Cancer Cell Division Regulated by AKT Investigators show that rapidly proliferating cancer cells can divide asymmetrically to produce slowly proliferating “G0-like” progeny that are enriched following chemotherapy in breast cancer patients. [Proc Natl Acad Sci U S A] HERC2 Interacts with Claspin and Regulates DNA Origin Firing and Replication Fork Progression Scientists show that HERC2 is a component of the DNA replication fork complex that plays a critical role in DNA elongation and origin firing. [Cancer Res] C-Kit Is Required for Growth and Survival of the Cells of Origin of Brca1-Mutation-Associated Breast Cancer To address the functional significance of c-Kit expression in the mammary gland, c-Kit– and c-Kit+ mammary epithelial subsets were isolated by flow cytometry, characterized for expression of lineage-specific cell markers and functionally analyzed by in vitro colony forming and in vivo transplantation assays. [Oncogene] Wnt–ß-Catenin–Tcf-4 Signaling-Modulated Invasiveness Is Dependent on Osteopontin Expression in Breast Cancer In this report, researchers have examined the importance of the regulation of osteopontin in human breast cancer. [Br J Cancer] Contribution of Xanthine Oxidoreductase to Mammary Epithelial and Breast Cancer Cell Differentiation in Part Modulates Inhibitor of Differentiation-1 In the present study investigators hypothesized that the contribution of xanthine oxidoreductase to the development of the normal mammary gland may underlie its capacity to modulate breast cancer. [Mol Cancer Res] Breast Field Cancerization: Isolation and Comparison of Telomerase Expressing Cells in Tumor and Tumor Adjacent, Histologically Normal Breast Tissue In the current study, scientists first validated a reporter for measuring levels of human telomerase reverse transcriptase (hTERT) promoter activity in early passage human mammary epithelial cells (HMECs) and then used this reporter to compare hTERT promoter activity in HMECs derived from tumor and paired tumor-adjacent histologically-normal tissues 1, 3 and 5 cm from the tumor. [Mol Cancer Res] CLINICAL RESEARCH Dextromethorphan as a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment In this pharmacokinetic study, researchers investigated the value of dextromethorphan, a known probe drug for both CYP2D6 and CYP3A enzymatic activity, as a potential phenotyping probe for tamoxifen pharmacokinetics. [J Clin Oncol] Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients with Node-Positive Breast Cancer The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer. [J Clin Oncol] Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data from NCCTG N9831 and NSABP B-31 Data demonstrates consistent disease-free survival and overall survival advantages of adjuvant trastuzumab over time, with the longest follow-up reported to date. [J Clin Oncol] Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women with Reduced CYP2D6 Metabolism: A Multicenter Study Scientists examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with intermediate CYP2D6 metabolism. [J Clin Oncol] Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from RegistHER For patients with HER2-positive metastatic breast cancer evaluated in registHER, the use of trastuzumab, chemotherapy, and surgery following central nervous system metastases were each associated with longer survival. [Clin Cancer Res] |